Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions

U. Coskun; N. Bukan; B. Sancak; N. Günel; S. Ozenirler; A. Unal; A. Yucel

Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions

U. Coskun
, N. Bukan
, B. Sancak
, N. Günel
, S. Ozenirler
, A. Unal
, A. Yucel

Gazi University

Research output: Contribution to journal › Article › peer-review

21 Citations (Scopus)

Abstract

Hepatocyte growth factor (HGF) is a potent stimulator of angiogenesis and cancer metastasis. Interleukin-6 (IL-6) is a pleiotropic cytokine that can act as an autocrine or paracrine growth factor in various tumor cells. In this study, we investigated the role of serum HGF and IL-6 levels to distinguish primary or metastatic liver tumors from benign liver lesions. Serum HGF and IL-6 levels were measured in 64 cancer patients and 12 healthy controls. Patients were divided into 5 groups: Group-1 (n=24): Breast cancer patients in complete remission without any liver lesion, Group-2 (n=8): Breast cancer patients in complete remission with benign liver lesion, Group-3 (n=10): Breast cancer patients with liver metastasis, Group-4 (n=11): Metastatic breast cancer patients without liver metastasis, Group-5 (n=11): Patients with hepatocellular carcinoma. Group-6 (n=12): Healthy controls. Serum HGF levels were found to be higher in group-5 (606.4±255.8 pg/ml) than those in group-1 (*305.6±42.3 pg/ml), group-2 (*293.9±44.8 pg/ml), group-4 (**358.4±81.9 pg/ml) and group-6 (*305. 8±24.9 pg/ml) (*p<0.001, **p<0.05). Patients in group-3 (448.9± 157.3 pg/ml) had higher serum HGF levels than those in group-1, group-2 and group-6 (p<0.05). Serum IL-6 levels were found to be higher in group-5 (54.9±37.4 pg/ml) than those in group-1 (9.7±6.4 pg/ml), group-2 (9.5±4.8 pg/ml), group-4 (17.6±19.6 pg/ml) and group-6 (12.6±5.2 pg/ml, p<0.05). Patients in group-3 (32.5±36.9 pg/ml) had higher serum IL-6 levels than those in group-1,2 and group-6, but these were not statistically significant (p>0.05). This study showed that primer and metastatic liver tumors had higher serum HGF and IL-6 levels than other patients and controls. Measurements of these markers in serum may be used to distinguish patients with primer liver tumors or breast cancer patients with liver metastasis from those with benign liver lesions or non-metastatic patients.

Original language	English
Pages (from-to)	209-213
Number of pages	5
Journal	Neoplasma
Volume	51
Issue number	3
Publication status	Published - 2004
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Breast cancer
Hepatocellular carcinoma
Hepatocyte growth factor
Interleukin-6
Liver tumors

Cite this

@article{e1ab76ba144445528d27e3b0d2560c9a,

title = "Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions",

abstract = "Hepatocyte growth factor (HGF) is a potent stimulator of angiogenesis and cancer metastasis. Interleukin-6 (IL-6) is a pleiotropic cytokine that can act as an autocrine or paracrine growth factor in various tumor cells. In this study, we investigated the role of serum HGF and IL-6 levels to distinguish primary or metastatic liver tumors from benign liver lesions. Serum HGF and IL-6 levels were measured in 64 cancer patients and 12 healthy controls. Patients were divided into 5 groups: Group-1 (n=24): Breast cancer patients in complete remission without any liver lesion, Group-2 (n=8): Breast cancer patients in complete remission with benign liver lesion, Group-3 (n=10): Breast cancer patients with liver metastasis, Group-4 (n=11): Metastatic breast cancer patients without liver metastasis, Group-5 (n=11): Patients with hepatocellular carcinoma. Group-6 (n=12): Healthy controls. Serum HGF levels were found to be higher in group-5 (606.4±255.8 pg/ml) than those in group-1 (*305.6±42.3 pg/ml), group-2 (*293.9±44.8 pg/ml), group-4 (**358.4±81.9 pg/ml) and group-6 (*305. 8±24.9 pg/ml) (*p<0.001, **p<0.05). Patients in group-3 (448.9± 157.3 pg/ml) had higher serum HGF levels than those in group-1, group-2 and group-6 (p<0.05). Serum IL-6 levels were found to be higher in group-5 (54.9±37.4 pg/ml) than those in group-1 (9.7±6.4 pg/ml), group-2 (9.5±4.8 pg/ml), group-4 (17.6±19.6 pg/ml) and group-6 (12.6±5.2 pg/ml, p<0.05). Patients in group-3 (32.5±36.9 pg/ml) had higher serum IL-6 levels than those in group-1,2 and group-6, but these were not statistically significant (p>0.05). This study showed that primer and metastatic liver tumors had higher serum HGF and IL-6 levels than other patients and controls. Measurements of these markers in serum may be used to distinguish patients with primer liver tumors or breast cancer patients with liver metastasis from those with benign liver lesions or non-metastatic patients.",

keywords = "Breast cancer, Hepatocellular carcinoma, Hepatocyte growth factor, Interleukin-6, Liver tumors",

author = "U. Coskun and N. Bukan and B. Sancak and N. G{\"u}nel and S. Ozenirler and A. Unal and A. Yucel",

year = "2004",

language = "English",

volume = "51",

pages = "209--213",

journal = "Neoplasma",

issn = "0028-2685",

publisher = "AEPress, s.r.o.",

number = "3",

}

TY - JOUR

T1 - Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions

AU - Coskun, U.

AU - Bukan, N.

AU - Sancak, B.

AU - Günel, N.

AU - Ozenirler, S.

AU - Unal, A.

AU - Yucel, A.

PY - 2004

Y1 - 2004

N2 - Hepatocyte growth factor (HGF) is a potent stimulator of angiogenesis and cancer metastasis. Interleukin-6 (IL-6) is a pleiotropic cytokine that can act as an autocrine or paracrine growth factor in various tumor cells. In this study, we investigated the role of serum HGF and IL-6 levels to distinguish primary or metastatic liver tumors from benign liver lesions. Serum HGF and IL-6 levels were measured in 64 cancer patients and 12 healthy controls. Patients were divided into 5 groups: Group-1 (n=24): Breast cancer patients in complete remission without any liver lesion, Group-2 (n=8): Breast cancer patients in complete remission with benign liver lesion, Group-3 (n=10): Breast cancer patients with liver metastasis, Group-4 (n=11): Metastatic breast cancer patients without liver metastasis, Group-5 (n=11): Patients with hepatocellular carcinoma. Group-6 (n=12): Healthy controls. Serum HGF levels were found to be higher in group-5 (606.4±255.8 pg/ml) than those in group-1 (*305.6±42.3 pg/ml), group-2 (*293.9±44.8 pg/ml), group-4 (**358.4±81.9 pg/ml) and group-6 (*305. 8±24.9 pg/ml) (*p<0.001, **p<0.05). Patients in group-3 (448.9± 157.3 pg/ml) had higher serum HGF levels than those in group-1, group-2 and group-6 (p<0.05). Serum IL-6 levels were found to be higher in group-5 (54.9±37.4 pg/ml) than those in group-1 (9.7±6.4 pg/ml), group-2 (9.5±4.8 pg/ml), group-4 (17.6±19.6 pg/ml) and group-6 (12.6±5.2 pg/ml, p<0.05). Patients in group-3 (32.5±36.9 pg/ml) had higher serum IL-6 levels than those in group-1,2 and group-6, but these were not statistically significant (p>0.05). This study showed that primer and metastatic liver tumors had higher serum HGF and IL-6 levels than other patients and controls. Measurements of these markers in serum may be used to distinguish patients with primer liver tumors or breast cancer patients with liver metastasis from those with benign liver lesions or non-metastatic patients.

AB - Hepatocyte growth factor (HGF) is a potent stimulator of angiogenesis and cancer metastasis. Interleukin-6 (IL-6) is a pleiotropic cytokine that can act as an autocrine or paracrine growth factor in various tumor cells. In this study, we investigated the role of serum HGF and IL-6 levels to distinguish primary or metastatic liver tumors from benign liver lesions. Serum HGF and IL-6 levels were measured in 64 cancer patients and 12 healthy controls. Patients were divided into 5 groups: Group-1 (n=24): Breast cancer patients in complete remission without any liver lesion, Group-2 (n=8): Breast cancer patients in complete remission with benign liver lesion, Group-3 (n=10): Breast cancer patients with liver metastasis, Group-4 (n=11): Metastatic breast cancer patients without liver metastasis, Group-5 (n=11): Patients with hepatocellular carcinoma. Group-6 (n=12): Healthy controls. Serum HGF levels were found to be higher in group-5 (606.4±255.8 pg/ml) than those in group-1 (*305.6±42.3 pg/ml), group-2 (*293.9±44.8 pg/ml), group-4 (**358.4±81.9 pg/ml) and group-6 (*305. 8±24.9 pg/ml) (*p<0.001, **p<0.05). Patients in group-3 (448.9± 157.3 pg/ml) had higher serum HGF levels than those in group-1, group-2 and group-6 (p<0.05). Serum IL-6 levels were found to be higher in group-5 (54.9±37.4 pg/ml) than those in group-1 (9.7±6.4 pg/ml), group-2 (9.5±4.8 pg/ml), group-4 (17.6±19.6 pg/ml) and group-6 (12.6±5.2 pg/ml, p<0.05). Patients in group-3 (32.5±36.9 pg/ml) had higher serum IL-6 levels than those in group-1,2 and group-6, but these were not statistically significant (p>0.05). This study showed that primer and metastatic liver tumors had higher serum HGF and IL-6 levels than other patients and controls. Measurements of these markers in serum may be used to distinguish patients with primer liver tumors or breast cancer patients with liver metastasis from those with benign liver lesions or non-metastatic patients.

KW - Breast cancer

KW - Hepatocellular carcinoma

KW - Hepatocyte growth factor

KW - Interleukin-6

KW - Liver tumors

UR - https://www.scopus.com/pages/publications/3042575159

M3 - Article

C2 - 15254675

AN - SCOPUS:3042575159

SN - 0028-2685

VL - 51

SP - 209

EP - 213

JO - Neoplasma

JF - Neoplasma

IS - 3

ER -

Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions

Abstract

UN SDGs

Keywords

Other files and links

Fingerprint

Cite this